A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

NCT03918239 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
190
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Shire